Saredutant
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)- 2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 142001-63-6 |
| ATC code | None |
| PubChem | CID 104974 |
| IUPHAR ligand | 2111 |
| ChemSpider | 94726  |
| ChEMBL | CHEMBL308148 |
| Chemical data | |
| Formula | C31H35Cl2N3O2 |
| Mol. mass | 552.5345 g/mol |
|
|
|
|
 (what is this?) (verify) |
|
Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[1]
[edit] See also
[edit] References
- ^ http://www.sanofi-aventis.com/binaries/Lettre18_FR_Web_acc_tcm29-25341.pdf Letter to the stockholders of Sanofi-Aventis on May 2009
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
